| 0 (0%) | 04-23 03:04 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.43  |
1-year : | 11.49 |
| Resists | First : | 8.93 |
Second : | 9.84 |
| Pivot price | 8.34 |
|||
| Supports | First : | 7.46 |
Second : | 6.21 |
| MAs | MA(5) : | 7.85 |
MA(20) : | 8.41 |
| MA(100) : | 6.36  |
MA(250) : | 4.83 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 5.7 |
D(3) : | 9 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 9.84 | Low : | 2.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ORN ] has closed above bottom band by 7.1%. Bollinger Bands are 44.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.87 - 7.91 | 7.91 - 7.94 |
| Low: | 7.38 - 7.42 | 7.42 - 7.46 |
| Close: | 7.45 - 7.51 | 7.51 - 7.57 |
Fri, 19 Apr 2019
Concert review: Maestro Choo Hoey returns with clarity and sprightly leadership - The Straits Times
Tue, 19 Feb 2019
Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 32 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 8.4 (%) |
| Held by Institutions | 68.4 (%) |
| Shares Short | 450 (K) |
| Shares Short P.Month | 200 (K) |
| EPS | -0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.73 |
| Profit Margin | -2.6 % |
| Operating Margin | 2.8 % |
| Return on Assets (ttm) | -1.4 % |
| Return on Equity (ttm) | -13.8 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 21.94 |
| EBITDA (p.s.) | 0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 17 (M) |
| Levered Free Cash Flow | 25 (M) |
| PE Ratio | -13.66 |
| PEG Ratio | -4.2 |
| Price to Book value | 2.01 |
| Price to Sales | 0.34 |
| Price to Cash Flow | 14.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|